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Abstract
Objective The objective of this study was to assess the validity of the Cornerstone Diabetes Simulation (CDS), a Microsoft 
 Excel®-based patient-level simulation for type 2 diabetes mellitus based on risk equations from the revised United Kingdom 
Prospective Diabetes Study Outcomes Model (UKPDS-OM2, also known as UKPDS 82).
Methods Three levels of validation were conducted. Internal validation was assessed through independent review and model 
stress-testing. External validation was addressed by populating the CDS with baseline characteristics and treatment effects 
from three major diabetes clinical trials used in the Fifth Mount Hood Diabetes Challenge (MH5) for computer simulation 
models. Cross-validation of predicted outcomes was tested versus eight models that participated in the MH5. Simulated 
results were compared with observed clinical outcomes via the coefficient of determination (R2) for both the absolute risk 
of each clinical outcome and the difference in absolute risk between control and intervention arm in each trial. We ensured 
transparency of all model inputs and assumptions in reporting.
Results The CDS could be used to predict 18 of 39 single and composite endpoints across the three trials. The model obtained 
an R2 of 0.637 for predicted versus observed absolute risks, and an R2 of 0.442 for predicted versus observed risk differences 
between control and intervention. Among the other eight models, only one obtained a higher R2 value under both definitions, 
albeit based on only four predicted endpoints.
Conclusions The CDS provides good predictions of diabetes-related complications when compared to observed trial out-
comes and previously validated models. The model has value as a validated tool in cost-effectiveness evaluations.
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Key Points for Decision Makers 
Compared with existing diabetic models, simulations 
based on the revised United Kingdom Prospective Dia-
betes Study (UKPDS) risk equations perform favorably 
well in predicting risk differences.
Diabetic models based on the revised UKPDS risk 
equations, such as the Cornerstone Diabetes Simulation 
presented herein, are thus potentially suitable for cost-
effectiveness evaluations, which are mainly driven by 
risk differences.
This study highlights the importance of full transparency 
in documenting model inputs to ensure reproducibility of 
simulation results.
1 Introduction
Disease modeling is commonly employed to evaluate 
the clinical and economic outcomes associated with new 
medical interventions and provides useful information for 
decision makers to optimize allocation of limited health 
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for the challenge [1]. This analysis thus allows assessment 
of both the cross-validity and external validity of the CDS.
2  Methods
2.1  Model Overview
The CDS is an individual patient-level, Monte Carlo simu-
lation model developed to determine the long-term health 
outcomes and economic consequences of managing patients 
with T2DM. The model was programmed in Microsoft 
 Excel® 2010. The model utilizes risk equations from the 
UKPDS-OM2 [5] to estimate the incidence of diabetes com-
plications and all-cause mortality in a cohort of patients with 
T2DM in 1-year time increments over a user-defined time 
horizon (maximum: 100 years). A list of outcomes predicted 
by the UKPDS-OM2 risk equations and their predictive risk 
factors (i.e., input variables) are summarized in Electronic 
Supplementary Material (ESM) Appendix Tables A1–A3. 
The CDS is designed to evaluate a control arm and an inter-
vention arm, each of which consists of up to three lines of 
therapy. Each line of therapy may have a treatment effect in 
reducing glycated hemoglobin  (HbA1C), body mass index 
(BMI), low-density lipoprotein (LDL), and/or systolic blood 
pressure (SBP). Therapy switching is dependent on reaching 
user-prespecified thresholds for  A1C and/or time on therapy. 
The model allows the user to independently specify baseline 
values and time-path assumptions for all patient characteris-
tics, treatment sequences and effects, and treatment switch-
ing thresholds. In addition to predicting the cumulative inci-
dence of diabetes-related complications and mortality over 
the user-specified time horizon, the model also allows the 
user to specify cost and health utility inputs to generate cost-
effectiveness analysis outputs, including life-years gained, 
quality-adjusted life-years (QALYs), and the incremental 
cost-effectiveness ratio (ICER). A model structure diagram 
is presented in Fig. 1.
2.2  Validation
As suggested by the American Diabetes Association (ADA) 
guidelines for diabetes computer modeling [6], the CDS 
underwent an exhaustive validation exercise conducted in 
line with best validation practices [2, 6].
2.2.1  Internal Validation
The model was independently reviewed by LA, DTG, and 
LS, who were chosen based on their expertise in health 
economic modeling and diabetes treatment outcomes. The 
reviewers assessed the validity of the CDS model assump-
tions and calculations; final reviewer recommendations were 
resources. In the setting of chronic and progressive dis-
eases such as type 2 diabetes mellitus (T2DM), modeling 
is particularly helpful for extrapolating from clinical trials 
of typically short duration to predict the long-term clinical 
outcomes and costs of experimental interventions. Over the 
years, a variety of diabetes simulation models have been 
developed and since 1999, the Mount Hood Diabetes Chal-
lenge Network has organized a meeting bi-annually to com-
pare the structure and performance of participating health 
economic diabetes simulation models [1].
Health economic models need to gain the confidence of 
users for model predictions to be accepted in healthcare deci-
sion-making. The International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) and the Society for 
Medical Decision Making (SMDM) have jointly published 
recommendations for validation of health economic models 
[2]. The recommendations emphasize face validity (i.e., the 
model design, assumptions, data sources, and results are 
judged to be sound by experts), internal validity (i.e., model 
coding is correctly implemented), cross validity (i.e., model 
predictions are similar to those of other models analyzing 
the same problem), external validity (i.e., model results are 
consistent with actual real-world outcomes), and predictive 
validity (i.e., model predictions are consistent with outcomes 
observed in prospective clinical studies), with the latter two 
highlighted as the strongest forms of validation.
Risk equations developed by the United Kingdom Pro-
spective Diabetes Study (UKPDS) have been widely adopted 
by various diabetes modeling groups [3, 4]. Compared to 
the original UKPDS Outcomes Model (UKPDS-OM1), the 
latest, revised UKPDS Outcomes Model (UKPDS-OM2, 
also known as UKPDS 82) [5] risk equations incorporate 
a larger set of clinical risk factors as input to provide pre-
dictions for a greater number of outcomes for T2DM. The 
Cornerstone Diabetes Simulation (CDS) provides a user-
friendly, Microsoft  Excel®-based interface that implements 
the UKPDS-OM2 risk equations to predict clinical and 
cost outcomes associated with experimental treatments for 
T2DM. A unique feature of the CDS is that all calculations 
are implemented within a single Microsoft  Excel® file, pro-
viding the user full transparency in terms of reviewing the 
model calculations as well as maximum flexibility in terms 
of changing all model input values independently. However, 
as with any new implementation of simulation models, it is 
important to demonstrate the predictive validity of the CDS 
for potential users seeking to adopt this model in health eco-
nomic evaluations.
This analysis compared predictions by the CDS and those 
by eight well-established diabetes simulation models that 
participated in the Fifth Mount Hood Diabetes Challenge 
(MH5) in 2010 against actual outcomes observed in three 
major prospective diabetes clinical trials that were selected 
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discussed and incorporated into the final version. ZTS and 
SB completed model stress-testing, which included logic 
checks with extreme values (e.g., hazard ratio [HR] 1 or 
extreme values; percentages = 0%, 100%; costs set to $0, 
etc.), and varying input values and ensuring results changed 
in a direction consistent with expectation based on clinical 
insights. To ensure accurate coding of the UKPDS-OM2 
risk equations, diabetes complications and all-cause mortal-
ity simulated by the CDS for the UKPDS population over 
25 years were compared with predictions by the UKPDS-
OM2 and the actual outcomes observed in the UKPDS trial 
[5].
2.2.2  External Validation
Three landmark prospective diabetes clinical trials that 
were selected for the MH5 [1] were used to assess the exter-
nal and predictive validity of the CDS. These trials were 
specifically the lipid-lowering intervention from the ASPEN 
(Atorvastatin Study for Prevention of Coronary Heart Dis-
ease Endpoints in Non-Insulin-Dependent Diabetes Melli-
tus) trial [7], the blood glucose-lowering intervention from 
the ADVANCE (Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled 
Evaluation) trial [8], the blood pressure-lowering interven-
tion from the ACCORD (Action to Control Cardiovascular 
Risk in Diabetes) trial (ACCORD BP) [9], and the blood 
glucose-lowering intervention from the ACCORD trial 
(ACCORD BG) [10]. A total of eight diabetes simulation 
models participated in the MH5 and provided their predic-
tions for endpoints in these trials [1]. The cross-validity of 
the CDS could thus be assessed by comparing predictions of 
the CDS against those of the other eight models. Different 
event definitions between the UKPDS-OM2 risk equations 
(and hence the CDS) and those seen in the selected clini-
cal trials required additional calculations, assumptions, and 
Fig. 1  Cornerstone Diabetes 
Simulation model structure 
diagram
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exclusions. ESM Appendix Table A4 lists the endpoints of 
the three trials and, for those that could be estimated by the 
CDS, the definitions and assumptions used.
To run simulations for the validation, we populated the 
CDS separately for each arm (i.e., control and intervention) 
of each trial using the mean and standard error for predic-
tor variables as reported by the trial. Where a trial did not 
report the baseline value for a risk factor that was required as 
input by the CDS model, we used the reported baseline value 
for the same risk factor from another trial with a similar 
patient population (LDS [Lipids in Diabetes Study] [11] or 
intermediate-risk patients in the THIN [The Health Improve-
ment Network] database [12]). For each arm in each trial, 
the population was set to 250,000 and the simulated time 
horizon was the same as the reported median follow-up dura-
tion. If the reported duration of a trial was not a whole year, 
we rounded the duration up to a whole year since the CDS 
runs on fixed 1-year time increments. The model simulated 
baseline values for each patient using seeded-random num-
bers drawn from a uniform distribution between 1 and 0 
(inclusive). For binary variables, the patient was assigned 
the characteristic if the random number drawn was equal to 
or less than the population mean proportion. For continu-
ous variables, the baseline value was calculated using the 
inverse of the gamma cumulative function for  A1C and the 
inverse of the cumulative normal distribution function for 
other variables, with the drawn random number serving as 
the probability at which the inverse function was evaluated. 
In cases of a negative value, the model assumed the value of 
the population mean for that simulated patient.
In terms of time-paths of risk factors, where a trial 
reported the value of a risk factor at the end of the trial, 
we used either a linear or asymptotic function to model the 
reported change in value of that risk factor over the trial 
follow-up period. Generally, linear function was used to 
model BMI and smoker proportions over time and asymp-
totic function for all other clinical variables unless the source 
publication reported a time-path curve for a variable that 
largely appeared linear. Efficacy of the treatment under 
investigation was therefore captured through the time-paths 
of the risk factors (e.g.,  A1C, SBP). For all other risk factors 
for which the change in value over the trial follow-up period 
was not reported, we assumed these factors to be static over 
the simulation’s time horizon. A full description of baseline 
values, time-path assumptions, and references specific to 
the simulation of each clinical trial are presented in ESM 
Appendix Tables A5–A8.
We compared predicted outcomes by the CDS and the 
eight models that participated in the MH5 against actual 
observed outcomes as reported by the trial publications. 
We assessed the goodness-of-fit of predictions by each of 
the diabetes models by presenting scatterplots of observed 
versus predicted outcomes and calculating the coefficient 
of determination (R2). We evaluated the values of R2 for the 
absolute risk of each clinical outcome and the difference in 
absolute risk between control and intervention arm in each 
clinical trial.
3  Results
3.1  Internal Validation
Cumulative incidence of diabetes complications and all-
cause mortality predicted by the CDS for the UKPDS popu-
lation over 25 years were compared graphically to incidence 
curves reported by the UKPDS-OM2 source publication [5]. 
The predicted incidence curves closely matched the reported 
curves for all first-time events including mortality in the 
source publication (ESM Appendix Figure A1), even though 
baseline values for some predictor variables and individual 
patient data to inform time-paths of predictor variables and 
censoring were not publicly accessible. The observed dif-
ferences were considered sufficiently small given the data 
limitations for internal validation of the CDS.
3.2  External Validation
Figure 2 illustrates the relationship between observed ver-
sus predicted absolute risks of trial endpoints in control 
and intervention arms by the CDS and each of the diabe-
tes simulation models that participated in the MH5. There 
were a total of 39 single and composite endpoints across 
the three clinical trials selected for the MH5. Overall, the 
CDS could be used to evaluate 18 of those endpoints. The 
R2 value between the predicted and observed absolute risks 
for the CDS was 0.637. Of the eight models that participated 
in the MH5, only two models achieved a higher R2 value: 
0.724 for the Centers for Disease Control and Prevention-
RTI Diabetes Cost-effectiveness Model (CDC-RTI), which 
predicted a total of 20 endpoints, and 0.733 for the UKPDS 
Risk Engine (UKPDS RE), which predicted only four end-
points (Table 1). The CDS had an improved fit compared to 
the UKPDS-OM1 model (R2 0.616), the predecessor to the 
UKPDS-OM2 model on which the CDS is based.
The coefficient of determination was also evaluated for 
each diabetes model between the predicted and observed risk 
differences. A risk difference was calculated as the abso-
lute risk of a given trial endpoint in the control arm minus 
that in the intervention arm. The R2 value calculated under 
this definition was 0.442 for the CDS; only the UKPDS RE 
model was associated with a higher value (R2 0.665) based 
on four predicted endpoints (Table 1). The R2 value under 
this definition for the UKPDS-OM1 was 0.290, again lower 
than the CDS.
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Fig. 2  Scatterplots of observed absolute risks (on the horizontal axis) 
versus predicted absolute risks by each diabetes simulation model (on 
the vertical axis) for the control and intervention arm for each clini-
cal trial selected for the Fifth Mount Hood Diabetes Challenge, along 
with fitted linear regression equations and calculated coefficients of 
determination (R2). CARDIFF Cardiff Research Consortium Model, 
CDC-RTI Centers for Disease Control and Prevention-RTI Diabetes 
Cost-effectiveness Model, CDS Cornerstone Diabetes Simulation, 
EBMI Evidence-Based Medicine Integrator Simulator, ECHO-T2DM 
Economics and Health Outcomes in Type 2 Diabetes Mellitus Model, 
IMS CORE IMS CORE Diabetes Model, MICHIGAN Michigan 
Model for Diabetes, UKPDS-OM1 United Kingdom Prospective Dia-
betes Study Outcomes Model, UKPDS RE United Kingdom Prospec-
tive Diabetes Study Risk Engine
Table 1  Summary of validation 
analysis results for clinical trials 
selected for the Fifth Mount 
Hood Diabetes Challenge
CARDIFF Cardiff Research Consortium Model, CDC-RTI Centers for Disease Control and Prevention-RTI 
Diabetes Cost-effectiveness Model, CDS Cornerstone Diabetes Simulation, EBMI Evidence-Based Med-
icine Integrator Simulator, ECHO-T2DM Economics and Health Outcomes in Type 2 Diabetes Mellitus 
Model, IMS CORE IMS CORE Diabetes Model, MICHIGAN Michigan Model for Diabetes, UKPDS-OM1 
United Kingdom Prospective Diabetes Study Outcomes Model, UKPDS RE United Kingdom Prospective 
Diabetes Study Risk Engine
a Risk difference is defined as the absolute risk of a given outcome in the control arm minus that in the 
intervention arm
b Denotes a model with a higher coefficient of determination than the CDS model
Diabetes model Coefficient of determination 
(absolute risk)
Coefficient of determination 
(risk  differencea)
Endpoints predicted 
by model (total = 45)
CDS 0.637 0.442 18
IMS CORE 0.496 0.113 34
MICHIGAN 0.212 0.041 23
ECHO-T2DM 0.519 0.325 33
UKPDS-OM1 0.616 0.290 21
UKPDS RE 0.733b 0.665b 4
CDC-RTI 0.724b 0.212 20
CARDIFF 0.536 0.034 15
EBMI 0.134 0.418 17
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Detailed results of all the diabetes simulation models’ 
predicted outcomes versus actual trial outcomes are sum-
marized in ESM Appendix Tables A9–A13 (also see ESM 
Appendix Figures A2–A11 for scatterplots). When compar-
ing specific trial endpoints predicted by the CDS, several 
important findings were noted:
• Although the CDS’s predicted absolute risks were con-
sistent with observed absolute risks for most endpoints, 
the model overestimated the cumulative incidence of 
all-cause mortality in the ADVANCE trial and both 
the blood pressure and blood glucose interventions of 
the ACCORD trial. A similar finding was noted for the 
UKPDS-OM1.
• Compared to absolute risks, the risk differences predicted 
by the CDS were generally more consistent with the risk 
differences observed in the trials. For example, although 
the CDS overestimated the absolute risk of all-cause 
mortality in both control and intervention arms of the 
ADVANCE trial, the risk difference in all-cause mortal-
ity as predicted by the model was similar to the actual 
value observed in the trial (ESM Table A11).
• Similarly, the relative risks predicted by the CDS were 
generally closer to those observed in the trials.
4  Discussion
This study demonstrated the external and cross-validity of 
the CDS model, which performed well in predicting absolute 
risks and risk differences in three prospective diabetes clini-
cal trials used by the MH5. The CDS, based on the UKPDS-
OM2 risk equations, obtained a similar coefficient of deter-
mination for predicted absolute risks with the UKPDS-OM1, 
the predecessor to the UKPDS-OM2. This result is consist-
ent with findings reported by the Cardiff Diabetes Model 
group, who found that the UKPDS-OM2 risk equations 
exhibit similar levels of external validity to the UKPDS-
OM1 [4]. In our study, although the coefficient of determina-
tion achieved by the CDS was lower than that achieved by 
the UKPDS RE, the latter model’s goodness-of-fit was only 
assessed based on four predicted endpoints, limiting mean-
ingful interpretation of these findings. An alternative model 
to the CDS exhibiting a similar goodness-of-fit based on a 
comparable number of predicted endpoints was the CDC-
RTI model.
Most importantly, results from our validation analysis 
suggest that the CDS demonstrates a high level of valid-
ity for predicting absolute risk reductions associated with 
diabetes treatments. This conclusion is supported by the 
finding that when the goodness-of-fit was assessed between 
the predicted and observed risk differences between con-
trol and intervention arms, the CDS performed similarly to 
previously validated models, as evident by the achieved coef-
ficient of determination, which was higher than all models 
except the UKPDS RE. Given this finding, the CDS model 
may be suitable for cost-effectiveness evaluations, since 
the values of ICERs are usually driven by risk differences 
between control and intervention, rather than absolute risks.
Our external validation analysis results are also consistent 
with the main finding from the MH5: the models that par-
ticipated in the MH5 generally predicted the relative risks of 
clinical events better than the absolute risks [1]. This is espe-
cially the case for mortality predictions. Similarly, the CDS 
in general achieved better predictions of risk differences of 
clinical events between control and intervention than abso-
lute risks of events. In particular, the CDS overestimated the 
absolute mortality risk for each trial while contrastingly pro-
ducing reasonable approximations of relative and incremen-
tal risks of mortality between control and intervention arms. 
Additional research is needed to ascertain the reason(s) for 
the all-cause mortality overestimation using the UKPDS risk 
equations, and whether any adjustment to the risk equations 
is warranted for using the CDS to simulate all-cause mortal-
ity in patient populations outside of the UKPDS.
Our study faced several limitations. The most significant 
limitation was the aforementioned lack of baseline values 
of risk factors from the selected clinical trials to populate 
all inputs required by the CDS. The use of alternative val-
ues likely affected the accuracy of the model predictions. 
In addition, in our validation analysis many of the trial 
endpoints were not direct matches for outcomes predicted 
by the UKPDS-OM2 risk equations; as such, we had to 
develop formulas to approximate some of these endpoints 
using a combination of outcomes that could be calcu-
lated from the UKPDS-OM2 risk equations. This again 
likely contributed to some of the observed deviations from 
expected results. Furthermore, we assessed the goodness-
of-fit between observed and predicted outcomes by treating 
all endpoints equally in our calculations. However, depend-
ing on the specific needs and priorities of users of health 
economic models, certain endpoints might be considered 
more important than others in terms of accurate model 
predictions. We tried to address this issue by providing 
detailed summaries of all individual endpoint predictions 
by the CDS and other models. Additionally, using the MH5 
allowed us to perform cross-validation against established 
diabetes simulation models but limited the number of clini-
cal trials our model was used to simulate. Lastly, after the 
MH5 publication, several participant models were updated 
to incorporate UKPDS-OM2 risk equations, and new mod-
els such as the BRAVO (Building, Relating, Assessing, 
and Validating Outcomes) model based on the ACCORD 
trial population were recently developed and validated (the 
BRAVO model achieved a coefficient of determination of 
0.86 against 28 endpoints from trials used in the Fourth and 
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Fifth Mount Hood Diabetes Challenges) [13]. However, 
predictions by these updated models against the landmark 
clinical trials used by the MH5 are not fully available, and 
hence updated comparisons to these models were not con-
ducted in this analysis.
Our study highlights the importance of transparency of 
model inputs and assumptions in documentation of dis-
ease modeling. In our validation of the CDS, the primary 
challenge we faced was a lack of full documentation from 
existing publications for certain model baseline values and 
time-paths and we had to rely on either external sources 
or develop our own assumptions. We were thus unable to 
determine if the model input values and assumptions we 
employed were the same as those used by the other mod-
els when these modeling groups were completing the MH5. 
Following recommendations from the Eighth Mount Hood 
Challenge held in 2016 [14] regarding transparency of 
model input documentation, we reported all model baseline 
input values and time-paths used in our simulations. Com-
bined with the fact that the CDS model is implemented in 
Microsoft  Excel® in a fully transparent manner so that all 
model calculations and assumptions are fully visible to users 
and all model inputs may be independently varied by users, 
we ensure full transparency of our model inputs and repro-
ducibility of our simulation results by future investigations.
5  Conclusion
Following best practices for validating computer simula-
tion models, our analysis demonstrated that the CDS is a 
user-friendly simulation tool that can be used to adequately 
predict clinical outcomes in managing patients with T2DM. 
The model may be particularly useful for predicting treat-
ment effects and is potentially suitable for cost-effectiveness 
analyses. Future research to assess predictions of costs and 
cost effectiveness would complement this validation and 
provide useful information for decision makers to optimize 
health resource allocation.
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